No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
KALV KalVista Pharmaceuticals
- 11.370
- -0.450-3.81%
Close Jun 18 16:00 ET
479.68MMarket Cap-3644P/E (TTM)
11.820High11.280Low226.98KVolume11.770Open11.820Pre Close2.60MTurnover1.10%Turnover RatioLossP/E (Static)42.19MShares16.88052wk High5.41P/B235.35MFloat Cap7.21052wk Low--Dividend TTM20.70MShs Float129.108Historical High--Div YieldTTM4.57%Amplitude4.120Historical Low11.471Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Needham Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $35
Needham analyst Serge Belanger maintains $KalVista Pharmaceuticals(KALV.US)$ with a buy rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 41.9
Express News | Needham Reiterates Buy on KalVista Pharma, Maintains $35 Price Target
KalVista Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/18/2024 196.11% Needham $35 → $35 Reiterates Buy → Buy 05/03/2024 69.2% HC Wainwright & Co. $24 → $20 M
KalVista Seeks FDA OK of Sebetralstat for Hereditary-Angioedema Attacks
By Colin Kellaher KalVista Pharmaceuticals has filed for Food and Drug Administration approval of sebetralstat, a proposed oral on-demand treatment for hereditary-angioedema attacks in people ages 12
KalVista Submits New Drug Application For FDA Review Of Sebetralstat
Sebetralstat is a novel investigational oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 years and older.The
Express News | Kalvista Pharmaceuticals Inc: Plans to Commence a Pediatric Trial (Konfident-Kid) in Q3 2024
Comments
The recent share sale by the CEO and the absence of insider buying over the past year may raise concerns. The low level of insider ownership compared to most companies is also somewhat worrying. Caution is advised when considering buying KalVista Pharmaceuticals stock.
Have KalVista Pharmaceuticals Insiders Been Selling Stock?
$Pfizer(PFE.US$ Phase 3
$Regenxbio(RGNX.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Vertex Pharmaceuticals(VRTX.US$ Phase 3
$KalVista Pharmaceuticals(KALV.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$Applied Therapeutics(APLT.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3 ...
$Regenxbio(RGNX.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Vertex Pharmaceuticals(VRTX.US$ Phase 3
$KalVista Pharmaceuticals(KALV.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$Applied Therapeutics(APLT.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3 ...
20
1
The termination of the KVD824 trial may impact KalVista's financials and stock price, but the company remains focused on advancing its other drug, sebetralstat, and its oral Factor XIIa inhibitor program for HAE prophylaxis.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg